UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | F | G | H | J | K | L | M | N | O | P | S | T | V | W
Number of items: 79.


Al-Azraqi, A; Angus, B; Gokul, S; Sinha, D; Calvert, AH; Lunec, J; (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. British Journal of Cancer , 80 178 - ?.

Al-Mufti, RAM; Pedley, RB; Marshall, D; Begent, RHJ; Winslet, MCAH; K, EF; (1999) In vitro assessment of lipiodol targeted radiotherapy for primary and metastatic liver cancers. British Journal of Cancer , 79 pp. 1665-1671.

Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, PJ; Endicott, JA; Gibson, AE; (1999) In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors. British Journal of Cancer , 80 110 - ?.


Bagshawe, KD; Sharma, SK; Burke, PJ; Melton, RG; Knox, RJ; (1999) Developments with targeted enzymes in cancer therapy. CURRENT OPINION IN IMMUNOLOGY , 11 (5) pp. 579-583. 10.1016/S0952-7915(99)00004-7.

Batey, MA; Wright, JG; Simmonds, D; Proctor, M; Chapman, F; Fishwick, K; Azzabi, A; (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. British Journal of Cancer , 80 259 - ?.

Begent, RHJ; (1999) Targeting cancer therapy. In: BRITISH JOURNAL OF CANCER. (pp. 104 - 109). CHURCHILL LIVINGSTONE

Bilanges, B; Varrault, A; Basyuk, E; Rodriguez, C; Mazumdar, A; Pantaloni, C; Bockaert, J; (1999) Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene , 18 (27) pp. 3979-3988. 10.1038/sj.onc.1202933.

Bramwell, VHC; Steward, WP; Nooij, M; Whelan, J; Craft, AW; Grimer, RJ; Taminau, AHM; (1999) Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European osteosarcoma intergroup study. J CLIN ONCOL , 17 (10) 3260 - 3269.

Bridgewater, JA; Nelstrop, AE; Rustin, GJ; Gore, ME; McGuire, WP; Hoskins, WJ; (1999) Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol , 17 (2) pp. 501-508. 10.1200/JCO.1999.17.2.501.

Brooks, N; McHugh, PJ; Lee, M; Hartley, JA; (1999) The role of base excision repair in the repair of DNA adducts formed by a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size. ANTI-CANCER DRUG DES , 14 (1) 11 - 18.


Calabrese, CR; Thomas, HD; Batey, MA; Boritzki, T; Zhang, K; White, AW; Curtin, NJ; (1999) Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research , 5 543 - ?.

Calvert, AH; Ghokul, S; Al-Azraqi, A; Wright, J; Lind, M; Bailey, N; Highley, M; (1999) Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. SEMINARS IN ONCOLOGY , 26 (1) 90 - 94.

Calvert, AH; Hughes, AN; Calvert, PM; Plummer, RE; Highley, MS; (1999) MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. European Journal of Cancer , 35 1146 - ?.

Calvert, AH; Sessa, C; Hughes, A; Jochim, U; Calvert, P; Ghielmini, M; Renard, J; (1999) Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer , 35 1147 - ?.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl 6) 105 - 108.

Calvert, H; (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl ) pp. 105-108.

Calvert, H; (1999) An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. SEMINARS IN ONCOLOGY , 26 (2) 3 - 10.

Calvert, PM; Highley, MS; Hughes, AN; Plummer, ER; Azzabi, AST; Verrill, MW; Camboni, MG; (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. Clinical Cancer Research , 5 333 - ?.

Casey, JL; Pedley, RB; King, DJ; Boden, R; Chapman, AP; Yarranton, GT; Begent, RHJ; (1999) Improved tumour targeting of di-Fab ' fragments modified with polyethylene glycol. TUMOR TARGET , 4 (4) 235 - 244.

Casey, JL; Pedley, RB; King, DJ; Green, AJ; Yarranton, GT; Begent, RHJ; (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. BRIT J CANCER , 81 (6) 972 - 980.

Cooke, SP; Pedley, RB; Boden, R; Holliger, P; Winter, G; Begent, RHJ; Chester, KA; (1999) Tumour targeting using MFE-23 :: TNF alpha fusion protein. BRIT J CANCER , 80 85 - 85.

Cooke, SP; Pedley, RBB; R, H; P, W; G, B; R H J and Chester, KA; (1999) Tumour targeting using MFE::TNF fusion protein. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 85-).

Curtin, NJ; Bowman, KJ; Turner, RN; Huang, B; Loughlin, PJ; Calvert, AH; Golding, BT; (1999) Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha(1)-acid glycoprotein binding. BRIT J CANCER , 80 (11) 1738 - 1746.

Curtin, NJ; Kyle, S; Wang, LZ; Durkacz, BW; White, AJ; Srinivasan, S; Griffin, RJ; (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. Clinical Cancer Research , 5 520 - ?.


Delaney, CA; Wang, LZ; Kyle, LZ; Srinivasan, S; White, AW; Curtin, NJ; Calvert, AH; (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. British Journal of Cancer , 80 62 - ?.


Flynn, AA; Green, AJ; Boxer, G; Pedley, RB; Begent, RHJ; (1999) A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. PHYS MED BIOL , 44 (7) N151 - N159.

Flynn, AA; Green, AJ; Boxer, GM; Casey, JL; Pedley, RB; Begent, RHJ; (1999) A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. INT J RADIAT ONCOL , 43 (1) 183 - 189.


Ghazal-Aswad, S; Tilby, MJ; Lind, M; Baily, N; Sinha, DP; Calvert, AH; Newell, DR; (1999) Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels. ANN ONCOL , 10 (3) 329 - 334.

GlynneJones, R; Saunders, MI; Hoskin, P; Phillips, H; (1999) A pilot study of continuous, hyperfractionated, accelerated radiotherapy in rectal adenocarcinoma. Clinical Oncology , 11 pp. 334-339.

Griffin, RJ; Barlow, HC; Curtin, NJ; Calvert, AH; Golding, BT; Newell, DR; Smith, PG; (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). Clinical Cancer Research , 5 564 - ?.

Grimaldi, KA; Bingham, JP; Hartley, JA; (1999) PCR-based assays for strand-specific measurement of DNA damage and repair. I. Strand-specific quantitative PCR. Methods Mol Biol , 113 pp. 227-240. 10.1385/1-59259-675-4:227.

Grimaldi, KA; McAdam, SR; Hartley, JA; (1999) PCR-based assays for strand-specific measurement of DNA damage and repair. II. Single-strand ligation-PCR. Methods Mol Biol , 113 pp. 241-255. 10.1385/1-59259-675-4:241.


Hargreaves, RHJ; O'Hare, CC; Hartley, JA; Ross, D; Butler, J; (1999) Cross-linking and sequence-specific alkylation of DNA by aziridinylquinones. 3. Effects of alkyl substituents. J MED CHEM , 42 (12) 2245 - 2250.

Hartley, JA; O'Hare, CC; Baumgart, J; (1999) DNA alkylation and interstrand cross-linking by treosulfan. BRIT J CANCER , 79 (2) 264 - 266.

Hartley, JM; Spanswick, VJ; Gander, M; Giacomini, G; Whelan, J; Souhami, RL; Hartley, JA; (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. CLIN CANCER RES , 5 (3) 507 - 512.

Hochhauser, D; Valkov, NI; Gump, JL; Wei, I; O'Hare, C; Hartley, J; Fan, JG; (1999) Effects of wild-type p53 expression on the quantity and activity of topoisomerase II alpha and beta in various human cancer cell lines. J CELL BIOCHEM , 75 (2) 245 - 257.

Hughes, A; Calvert, H; (1999) An update on thymidylate synthase inhibitors. ANN ONCOL , 10 (10) 1137 - 1139.

Hughes, AN; Rafi, I; Griffin, MJ; Calvert, AH; Newell, DR; Calvete, JA; Johnston, A; (1999) Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. CLIN CANCER RES , 5 (1) 111 - 118.

Hunalov, A; Robson, L; Perkins, SJ; Begent, RHJ; Chester, KA; (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. BRIT J CANCER , 80 51 - 51.


Joiner, MC; Marples, B; Lambin, P; Short, S; Turesson, I; (1999) Low-dose hypersensitivity: current status and possible mechanisms. International Journal of Radiation Oncology Biology Physics , 49 (2) pp. 379-389.


Koberle, B; Masters, JRW; Hartley, JA; Wood, RD; (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. CURR BIOL , 9 (5) 273 - 276.


Lee, SM; Radford, JA; Ryder, WD; Deakin, DP; Morgenstern, OR; Scarffe, JH; Crowther, D; (1999) Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. Bone Marrow Transplantation , 24 (3) pp. 271-277.

Leevers, SJ; Vanhaesebroeck, B; Waterfield, MD; (1999) Signalling through phosphoinositide 3-kinases: the lipids take centre stage. CURRENT OPINION IN CELL BIOLOGY , 11 (2) pp. 219-225. 10.1016/S0955-0674(99)80029-5.


Maini, MK; Casorati, G; Dellabona, P; Wack, A; Beverley, PCL; (1999) T-cell clonality in immune responses. IMMUNOL TODAY , 20 (6) 262 - 266.

Mann, DJ; Child, ES; Swanton, C; Laman, H; Jones, N; (1999) Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J , 18 (3) pp. 654-663. 10.1093/emboj/18.3.654.

Mayer, A; Chester, KA; Flynn, AA; Begent, RH; (1999) Taking engineered anti-CEA antibodies to the clinic. J Immunol Methods , 231 (1-2) pp. 261-273.

McHugh, PJ; Gill, RD; Waters, R; Hartley, JA; (1999) Excision repair of nitrogen mustard-DNA adducts in Saccharomyces cerevisiae. NUCLEIC ACIDS RES , 27 (16) 3259 - 3266. Gold open access


Neidle, S; Mann, J; Rayner, EL; Baron, A; Opoku-Boahen, Y; Simpson, IJ; Smith, NJ; (1999) Symmetric bis-benzimidazoles: new sequence-selective DNA-binding molecules. CHEM COMMUN (10) 929 - 930.

Newell, DR; Arris, CE; Boyle, FT; Calvert, AH; Curtin, NJ; Dewsbury, P; Endicott, JA; (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Clinical Cancer Research , 5 124 - ?.

Nutting, C; Brada, M; Brazil, L; Sibtain, A; Saran, F; Westbury, C; Moore, A; (1999) Radiotherapy in the treatment of benign meningioma of the skull base. J Neurosurg , 90 (5) pp. 823-827. 10.3171/jns.1999.90.5.0823.


O'Neil, D; Swanton, C; Jones, A; Medd, PG; Rayment, N; Chain, B; (1999) IFN-gamma down-regulates MHC expression and antigen processing in a human B cell line. JOURNAL OF IMMUNOLOGY , 162 (2) pp. 791-798.


Page, MJ; Amess, B; Townsend, RR; Parekh, R; Herath, A; Brusten, L; Zvelebil, MJ; (1999) Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA , 96 (22) pp. 12589-12594. 10.1073/pnas.96.22.12589.

Pedley, RB; Sharma, SK; Boxer, GM; Boden, R; Stribbling, SM; Davies, L; Springer, CJ; (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res , 59 (16) pp. 3998-4003.

Pedley, RB; Sharma, SK; Boxer, GM; Boden, R; Stribbling, SM; Davies, L; Springer, CJ; (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. CANCER RES , 59 (16) 3998 - 4003.


Saunders, M; Dische, S; Barrett, A; Harvey, A; Griffiths, G; Parmar, M; (1999) Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial. Radiotherapy and Oncology , 52 (2) pp. 137-148. 10.1016/S0167-8140(99)00087-0.

Saunders, MI; Dische, S; Rojas, A; (1999) CHART (continuous, hyperfractionated, accelerated radiotherapy): a tale of two disciplines. Br J Cancer , 80 Sup pp. 110-115. 10.1038/sj.bjc.6690329.

Shamash, J; Lee, SM; Deakin, DP; Scarffe, JH; Morgenstern, GR; Chang, J; Gupta, RK; (1999) High dose chemotherapy (HDCT) with autologous haematopoietic support in recurrent or refractory Hodgkin’s lymphoma (HL). In: (Proceedings) British Cancer Research Meeting, Edinburgh.. (pp. 18-). British Journal of Cancer

Short, S; (1999) UNSPECIFIED In: (Proceedings) The Royal College of Radiologists Annual Scientific Meeting.

Short, S; (1999) The response of human glioma cells to low dose radiation. International journal of radiation biology , 75 pp. 1341-1348.

Short, S; Mayes, C; Woodcock, M; Joiner, MC; (1999) Low-dose hypersensitivity in the T98G glioblastoma cell line. International journal of radiation biology , 75 pp. 847-855.

Sirotnak, FM; Tolner, B; (1999) Carrier-mediated membrane transport of folates in mammalian cells. ANNU REV NUTR , 19 91 - 122.

Smith, PG; Barlow, HC; Loughlin, P; Huang, B; Bowman, KJ; Calvert, AH; Curtin, NJ; (1999) Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein. British Journal of Cancer , 80 82 - ?.

Smith, PG; Bewley, J; Gogel, JA; Calvert, AH; Newell, DR; Curtin, NJ; Chen, VJ; (1999) MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines. British Journal of Cancer , 80 83 - ?.

Smith, PG; Marshman, E; Calvert, AH; Newell, DR; Curtin, NJ; (1999) Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. SEMINARS IN ONCOLOGY , 26 (2) 63 - 67.

Spanswick, VJ; Hartley, JM; Ward, TH; Hartley, JA; (1999) Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. Methods Mol Med , 28 pp. 143-154. 10.1385/1-59259-687-8:143.

Spencer, DIR; Robson, L; Bhatia, J; Sharma, SK; Michael, NP; Whitelegg, NR; Rees, AR; (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. BRIT J CANCER , 80 52 - 52.

Steingruber, HE; Dunham, A; Coffey, AJ; Clegg, SM; Howell, GR; Maslen, GL; Scott, CE; (1999) High-resolution landmark framework for the sequence-ready mapping of Xq23-q26.1. GENOME RES , 9 (8) 751 - 762.

Summers, Y; Middleton, MR; Calvert, H; Lee, SM; Rustin, R; Newell, DR; Thatcher, N; (1999) Effect of temozolomide (TMZ) on central nervous system relapse in patients with advanced melanoma. In: (Proceedings) 1999 ASCO Annual Meeting/35th Annual Meeting, Atlanta, GA.. (pp. 531a-). Proceedings of the American Society of Clinical Oncology

Swanton, C; Card, GL; Mann, D; McDonald, N; Jones, N; (1999) Overcoming inhibitions: subversion of CKI function by viral cyclins. Trends Biochem Sci , 24 (3) pp. 116-120.


Tolner, B; Singh, A; Esaki, T; Roy, K; Sirotnak, FM; (1999) Transcription of the mouse RFC-1 gene encoding a folate transporter. Multiplicity and properties of promoters with minimum requirements for their basal activity. GENE , 231 (1-2) 163 - 172.


Vanhaesebroeck, B; Higashi, K; Raven, C; Welham, M; Anderson, S; Brennan, P; Ward, SG; (1999) Autophosphorylation of p110delta phosphoinositide 3-kinase: a new paradigm for the regulation of lipid kinases in vitro and in vivo. EMBO J , 18 (5) pp. 1292-1302. 10.1093/emboj/18.5.1292.

Vanhaesebroeck, B; Jones, GE; Allen, WE; Zicha, D; Hooshmand-Rad, R; Sawyer, C; Wells, C; (1999) Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. NATURE CELL BIOLOGY , 1 (1) pp. 69-71. 10.1038/9045.

Vanhaesebroeck, B; Waterfield, MD; (1999) Signaling by distinct classes of phosphoinositide 3-kinases. EXPERIMENTAL CELL RESEARCH , 253 (1) pp. 239-254. 10.1006/excr.1999.4701.


Webley, SD; Francis, R; Begent, RHJ; Hartley, JA; Hochhauser, D; (1999) Measurement of the critical DNA lesions produced by antibody directed enzyme prodrug therapy (ADEPT). BRIT J CANCER , 80 47 - 47.

Wedderburn, LR; Maini, MK; Patel, A; Beverley, PCL; Woo, P; (1999) Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. INT IMMUNOL , 11 (4) 535 - 543.

Whelan, J; Hoare, D; Leonard, P; (1999) Omeprazole does not alter plasma methotrexate clearance. Cancer Chemother Pharmacol , 44 (1) pp. 88-89. 10.1007/s002800050949.

Wilson, SC; Howard, PW; Forrow, SM; Hartley, JA; Adams, LJ; Jenkins, TC; Kelland, LR; (1999) Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2,1-c][1,4]benzodiazepine system. J MED CHEM , 42 (20) 4028 - 4041.

Woll, P; Judson, I; Lee, SM; Rodenhuis, S; Nielsen, OS; Buesa, JM; Lorigan, PC; (1999) Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma group. European Journal of Cancer , 35 (3) pp. 410-412.

Wong, KCK; Meyer, T; Harding, DI; Dick, JRT; Vrbova, G; Greensmith, L; (1999) Integrins at the neuromuscular junction are important for motoneuron survival. EUR J NEUROSCI , 11 (9) 3287 - 3292.

This list was generated on Sun Mar 26 03:58:02 2017 BST.